Skip to content

Study · Animal study (in vivo) · rat and rhesus monkey · 1982

7 results

SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.

Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless

Life sciences1 Sept 1982Cited by 811 (Europe PMC)

PMID6128648 (opens in a new tab)DOI10.1016/0024-3205(82)90087-x (opens in a new tab)PepBankPUB-06128648
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Activity measurement

    In rats, SMS 201-995 was at least 20 times more active than somatostatin, depending on the test system.

    In plain wordsIn rats, SMS 201-995 was at least 20 times more active than somatostatin, depending on the test system.

    Peptide
    Octreotide
    Outcome
    IncreaseIn vivo activity
    Study

    ratn: not reported in source

    Comparator
    Somatostatin
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Relative activity
    ≥ 20 times
    versus somatostatin, depending on test system

    Source sentences

    Summary
    which in vivo in rat and rhesus monkey is (depending on test system) at least 20 times more active than somatostatin, which is much longer acting
  2. 02AnimalAnimal study (in vivo)Activity measurement

    In rhesus monkeys, SMS 201-995 was at least 20 times more active than somatostatin, depending on the test system.

    In plain wordsIn rhesus monkeys, SMS 201-995 was at least 20 times more active than somatostatin, depending on the test system.

    Peptide
    Octreotide
    Outcome
    IncreaseIn vivo activity
    Study

    rhesus monkeyn: not reported in source

    Comparator
    Somatostatin
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Relative activity
    ≥ 20 times
    versus somatostatin, depending on test system

    Source sentences

    Summary
    which in vivo in rat and rhesus monkey is (depending on test system) at least 20 times more active than somatostatin, which is much longer acting
  3. 03AnimalAnimal study (in vivo)Activity measurement

    In rats, SMS 201-995 acted much longer than somatostatin.

    In plain wordsIn rats, SMS 201-995 acted much longer than somatostatin.

    Peptide
    Octreotide
    Outcome
    IncreaseDuration of action
    Study

    ratn: not reported in source

    Comparator
    Somatostatin
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    which in vivo in rat and rhesus monkey is (depending on test system) at least 20 times more active than somatostatin, which is much longer acting
  4. 04AnimalAnimal study (in vivo)Activity measurement

    In rhesus monkeys, SMS 201-995 acted much longer than somatostatin.

    In plain wordsIn rhesus monkeys, SMS 201-995 acted much longer than somatostatin.

    Peptide
    Octreotide
    Outcome
    IncreaseDuration of action
    Study

    rhesus monkeyn: not reported in source

    Comparator
    Somatostatin
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    which in vivo in rat and rhesus monkey is (depending on test system) at least 20 times more active than somatostatin, which is much longer acting
  5. 05AnimalAnimal study (in vivo)Activity measurement

    In rats, SMS 201-995 showed greater selectivity for inhibiting GH rather than insulin secretion than somatostatin.

    In plain wordsIn rats, SMS 201-995 inhibited growth hormone more selectively relative to insulin than somatostatin.

    Peptide
    Octreotide
    Outcome
    IncreaseGH versus insulin inhibition selectivity
    Study

    ratn: not reported in source

    Comparator
    Somatostatin
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    which in vivo in rat and rhesus monkey is (depending on test system) at least 20 times more active than somatostatin, which is much longer acting, and which moreover in both species is much more selective in inhibiting the secretion of growth hormone than that of insulin.
  6. 06AnimalAnimal study (in vivo)Activity measurement

    In rhesus monkeys, SMS 201-995 showed greater selectivity for inhibiting GH rather than insulin secretion than somatostatin.

    In plain wordsIn rhesus monkeys, SMS 201-995 inhibited growth hormone more selectively relative to insulin than somatostatin.

    Peptide
    Octreotide
    Outcome
    IncreaseGH versus insulin inhibition selectivity
    Study

    rhesus monkeyn: not reported in source

    Comparator
    Somatostatin
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    which in vivo in rat and rhesus monkey is (depending on test system) at least 20 times more active than somatostatin, which is much longer acting, and which moreover in both species is much more selective in inhibiting the secretion of growth hormone than that of insulin.
  7. 07AnimalAnimal study (in vivo)Safety outcome

    Laboratory animals tolerated SMS 201-995 well.

    In plain wordsLaboratory animals tolerated SMS 201-995 well.

    Peptide
    Octreotide
    Outcome
    Not applicableAnimal tolerability
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The compound is active by several routes of administration including the oral, is well tolerated both in laboratory animals and in man, and is currently undergoing preliminary clinical trial.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT02920567

Impact of Prophylactic Octreotide to Pancreatic Exocrine Secretion

Saint Vincent's Hospital, Korean = 282Jan 2014 to est. Jul 2018

Periampullary Tumors

Trial pageClinicalTrials.govUpdated 30 Sept 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.